Purdue Pharma L.P. and SpineThera, Inc. today announced that the companies have entered into an agreement that provides Purdue the exclusive option to acquire SpineThera, Inc......
Purdue Pharma L.P. today announced successful completion of a first-in-human Phase 1 dose escalation study of tinostamustine in patients with relapsed or refractory hematological malignancies for which there are no available therapies.